Mergers & acquisitions
The deal will grow Evotec’s business into a comprehensive offering including biologics in therapeutic areas such as oncology, CNS, pain, inflammation, metabolics and infectious diseases.
The acquisition of Nuevolution and its Chemetics platform will expand Amgen’s ability to discover novel small molecules against difficult-to-drug targets.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. (“Just.Bio”) based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
The deal gives Amryt a toehold in the United States with the previously approved Juxtapid, a treatment for the inherited cholesterol disorder homozygous familial hypercholesterolaemia.
Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.
The companies said they planned to give the government additional time to review the deal. This is the third delay.
Acquisition Further Accelerates Medtronic’s Strategy to Transform Spinal Procedures and Improve Outcomes Through Complete Procedural Solutions
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
Under the terms of the deal, Pfizer will pay $340 million up front with another $470 million in payments contingent on milestones for the development and commercialization of TA-46 for the treatment of achondroplasia.
PRESS RELEASES